Skip to contentD
DiaMedica Therapeutics Inc.
D
DMACDiaMedica Therapeutics Inc. Released May 13, 2025, after the close
10-Q filed May 13, 2025, 43 days after period end · 0001437749-25-016488
Q1 2025 · 10-Q
Revenue—
Net Income-$7.71M-$7.71MN/M vs Q1 2024N/M vs Q4 2024 EPS, diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
—
Operating Income-$8,144,000N/M Operating Cash Flow-$7,149,000N/M Free Cash Flowderived-$7,161,000N/M ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end
+2.4% from the close of May 13, 2025 to the close of May 14, 2025, the first after the release.
after the close$3.93$4.02 Apr 22May 13Jun 5